Live Breaking News & Updates on க்யாத்லீந் ஃப்யாரந்
Stay updated with breaking news from க்யாத்லீந் ஃப்யாரந். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Merus N.V.: Merus to Participate in a Fireside Chat at the Jefferies Virtual Healthcare Conference and Triclonics ), today announced that Bill Lundberg, M.D., Chief Executive Officer of Merus, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Wednesday, June 2 at 9:00 a.m. ET. The live webcast of the presentation will be available on the Investors page of the Company s website. An archived presentation will be available on the Merus website for a limited time. About Merus Merusis a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics ....
Published: May 13, 2021 UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ®), today announced new collaborations in Israel, Italy and Spain to expand molecular screening opportunities for patients with cancers that may have neuregulin 1 (NRG1) fusions and to raise awareness of the Merus eNRGy clinical trial of its bispecific antibody zenocutuzumab (Zeno). In the collaborations, Merus plans to support molecular screenings for eligible patients with pancreatic adenocarcinoma in Israel and Italy, and with non-small cell lung cancer (NSCLC) in Spain, aimed to identify the presence of NRG1 fusions. Each collaborating organization in turn has agreed as follows: ....
(2) UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 28, 2021. (Nasdaq: MRUS) ( Merus , the Company , we , or our ), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced the company s selection for oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, being held virtually June 4-8, 2021. The presentation highlights updated interim clinical data for the targeted bispecific antibody, zenocutuzumab (Zeno), in NRG1 fusion positive (NRG1+) cancers. Merus is currently recruiting patients into the phase 1/2 eNRGy trial to assess the safety and anti-tumor activity of Zeno monotherapy in NRG1+ cancers. Oral Presentation: Title: Efficacy and safety of zenocutuzumab in advanced pancreas cancer and other solid tumors harboring NRG1 fusions ....
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Merus Granted FDA Fast Track Designation of Zenocutuzumab for the Treatment of Patients with . Merus N.V.January 7, 2021 GMT UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™) for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Zenocutuzumab (Zeno) for the treatment of patients with metastatic solid tumors harboring NRG1 gene fusions (NRG1+ cancers) that have progressed on standard of care therapy. ....
Merus N.V.: FDA erteilt Merus Fast-Track-Status für Zenocutuzumab zur Behandlung von Krebserkrankungen mit Neuregulin-1-Fusionen finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.